Larimar Therapeutics Reports FDA Clinical Hold On CTI-1601, Termination Of Recently Announced Private Placement Financing
Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia (FA) and other complex rare diseases, today